TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04219618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-Pump
Description: After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Pump
Description: A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
Study: NCT00539643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bead Block microspheres
Description: Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bead + Dox Arm
Description: Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
Study: NCT03304860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
Study: NCT01282671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
Study: NCT01740102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
Study: NCT04204213

Intervention type: BEHAVIORAL
Intervention: Tai Chi Exercise
Description: 8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
Study: NCT03149016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy-assisted Retraction
Description: Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
Study: NCT02585596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 1000mg/day
Description: YH23537 500mg 2 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 1000mg/day
Description: YH23537 500mg 2 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 2000mg/day
Description: YH23537 500mg 4 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 3000mg/day
Description: YH23537 500mg 6 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 3000mg/day
Description: YH23537 500mg 6 tab
Study: NCT01931995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS positively correlated DLPFC
Description: TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS to negatively correlated DLPFC
Description: TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
Study: NCT00964990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
Study: NCT02586519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurroSense Rx System
Description: The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SurroSense Rx System
Description: The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SurroSense Rx System
Description: The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur.
Study: NCT01901653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (SC16LD6.5)
Study: NCT02585596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: YH23537 500mg tab placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: YH23537 500mg tab placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: YH23537 500mg tab placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: YH23537 500mg tab placebo
Study: NCT00301080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04323228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement enriched in antioxidants
Description: the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose-containing placebo capsules
Description: The placebo group will receive an oral supplement at the same time in the same shape/size/color.
Study: NCT02761655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Strategies
Description: Memory strategies on encoding retention, retrieval, execution and monitoring
Study: NCT03347175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume controlled ventilation
Description: Volume controlled ventilation mode

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled ventilation
Description: Pressure controlled ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP mode
Description: CPAP mode only
Study: NCT03324659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Meditation
Description: The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
Study: NCT02810314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological battery
Description: neuropsychological battery including cognitive and behavioural tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resting state functional magnetic resonance image (rs-fMRI)
Description: rs-fMRI

Intervention type: OTHER
Group type: OTHER
Intervention: resting state functional magnetic resonance image (rs-fMRI)
Description: rs-fMRI
Study: NCT03036501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-Risdiplam
Description: \[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.
Study: NCT03990584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three irrigation activation methods
Description: passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional needle irrigation
Description: conventional needle irrigation
Study: NCT02990416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ionizing Radiation
Description: Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
Study: NCT03296709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPC z
Description: Installation of a preformed pediatric zircona crown

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPC m
Description: Installation of a preformed pediatric metal crown
Study: NCT05626764

Intervention type: OTHER
Intervention: QoL & irAEs determinants
Description: Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.

Intervention type: OTHER
Intervention: QoL & irAEs determinants
Description: Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
Study: NCT00553098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo low dose TBI
Study: NCT03484338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy
Description: ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Resolution Therapy
Description: ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
Study: NCT02766179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is used for 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnoguard
Description: Somnoguard is used for 6 weeks
Study: NCT02281760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
Study: NCT04665622

Intervention type: OTHER
Group type: OTHER
Intervention: Eye-Tracking / Neuropsychological evaluations
Description: Use of Eye-Tracking / Neuropsychological évaluations in 4 groups

Intervention type: OTHER
Group type: OTHER
Intervention: Eye-Tracking / Neuropsychological evaluations
Description: Use of Eye-Tracking / Neuropsychological évaluations in 4 groups

Intervention type: OTHER
Group type: OTHER
Intervention: Eye-Tracking / Neuropsychological evaluations
Description: Use of Eye-Tracking / Neuropsychological évaluations in 4 groups

Intervention type: OTHER
Group type: OTHER
Intervention: Eye-Tracking / Neuropsychological evaluations
Description: Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
Study: NCT02635724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Study: NCT00960752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gp100
Description: 1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gp100
Description: 1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gp100
Description: 1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R848 gel
Description: Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R848 gel
Description: Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-3
Description: 1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-3
Description: 1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-3
Description: 1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
Study: NCT02111837

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard infant formula with PL1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard infant formula with PL2
Study: NCT01455025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor granulocyte-colony stimulating factor
Description: Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5
Study: NCT01468779

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT03491098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Furoate spray
Description: Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisolone sodium phosphate 15mg
Description: three times per day for 1 week then gradual withdrawal over 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic sea water solution spray
Description: one puff in each nostril daily for 8 weeks
Study: NCT03748602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic outlet decompression
Description: TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
Study: NCT02378532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
Study: NCT01616771

Intervention type: DEVICE
Group type: OTHER
Intervention: Macintosh laryngoscope
Description: Glottis view assessment by direct visualization using Macintosh laryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: GVL selected by weight
Description: Glottis view assessment by GVL selected by weight which is usually selected first

Intervention type: DEVICE
Group type: OTHER
Intervention: smaller sized GVL
Description: Glottis view assessment by GVL which is smaller in one size than GVL selected by age